Cefotaxime Injection

[24 January 2017]

Products Affected - Description

Cefotaxime Sodium powder for solution for injection, West-Ward
1 gram, vial, 25 count (NDC 00143-9931-25)
2 gram vial, 25 count (NDC 00143-9933-25)
10 gram, vial, 1 count (NDC 00143-9935-01)
500 mg vial, 10 count (NDC 00143-9930-10)

Reason for the Shortage

  • Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
  • Baxter discontinued Claforan in late-2015.
  • West-Ward has cefotaxime on shortage due to increased demand.

Available Products

There are no presentations available.

Estimated Resupply Dates

West-Ward has cefotaxime 500 mg, 1 gram, 2 gram, and 10 gram vials on long-term back order and the company cannot estimate a release date.

Related Shortages


January 24, 2017; November 6, October 8, August 31, July 19, June 21, May 17 and 5, March 23, February 16 and 1, January 26 and 6, 2016; November 30, 17, 11 and 3, October 19, September 23, August 24 and 4, June 10, April 30 and 2, January 23, 2015; December 5, October 7, September 3, June 24, April 15, February 25, January 14, 2014; December 10, October 30, August 29 and 1, July 31, 2013, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing